SynthesisBMC oral health2026
Immunoregulatory role of resolvins in periodontal disease and treatment: a systematic review.
Synthesis in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resolvins are vital in resolving inflammation and are crucial in various disease activities. Their therapeutic potential has also been identified in several traditional systems. Resolvin-mediated pathways for resolving inflammation in periodontitis have demonstrated potential for preventing and treating periodontal lesions. The current systematic review investigated the application of resolvins (omega-3 Fatty acids, specifically EPA [Eicosapentaenoic acid] and DHA [docosahexaenoic acid]) as against placebo agents in managing periodontitis patients based on outcome parameters such as plaque, bleeding on probing and pocket depth reduction.A comprehensive search of electronic databases, including Clarivate™ Web of Science (WOS), Cochrane Library, Medline/PubMed, and Scopus, was conducted, along with grey literature search (e.g. medRxiv, bioRxiv and dissertations), to identify original peer-reviewed randomized controlled trials, clinical, and longitudinal studies published in English. Of the 379 records initially identified, 125 articles were screened after removing duplicates and those that didn’t meet the inclusion criteria. From these, 18 studies were evaluated in detail, and 9 articles qualified for inclusion in this systematic review.Four studies revealed a significantly reduced pocket depth (PD) and clinical attachment level (CAL) compared to placebo groups. In two studies, bleeding on probing (BOP) was markedly reduced, while three exhibited a significant reduction in gingival index (GI). Additionally, three out of seven investigations demonstrated a notable plaque index (PI) reduction. Although further research is required to confirm the role of resolvins in managing periodontal disease—whether used alone or in combination with other treatments—the findings from this study support their beneficial effects, even at doses below 300 mg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.